Search clinical trials for: Subfoveal CNV, AMD, ranibizumab

Total 661 results

Ophthotech Corporation

Terminated

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

Age-Related Macular Degeneration

United States
Egyptian Biomedical Research Network

Completed

Subfoveal Choroidal Thickness and Visual Acuity After Intravitreal Injection of Ranibizumab in Diabetic Retinopathy

Diabetic Retinopathy | Visual Acuity | Ranibizumab | Subfoveal Choroidal Thickness | Intravitreal

Egypt
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)

Age-related Macular Degeneration (AMD)

United States
Outlook Therapeutics, Inc.

Completed

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

Australia
Genentech, Inc.

Completed

Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration (LADDER)

Macular Degeneration

United States
Novartis Pharmaceuticals

Completed

Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre) (FLUID)

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD

Australia
Retinal Consultants of Arizona
Ophthotech Corporation

Completed

An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration

United States
David M. Brown, M.D.
Genentech, Inc.

Terminated

A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial) (SAVE)

Macular Degeneration | Age Related Macular Degeneration | Wet Age-Related Macular Degeneration | Choroidal Neovascular Membrane | Subfoveal Neovascular Age-Related Macular Degeneration

United States
Novartis

Completed

EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Choroidal Neovascularization

Taiwan, Korea, Republic of
Novartis

Completed

Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization (CNV) | Secondary to Age-related Macular Degeneration (AMD)

Germany, Belgium, Spain, Netherlands, United Kingdom, Hungary, Turkey, Israel, Portugal, Australia
University of Illinois at Chicago
ICON Bioscience Inc

Completed

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) (20089/Combo)

Age-Related Macular Degeneration | Choroidal Neovascularization

United States
Genentech, Inc.

Completed

A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration

Macular Degeneration
Genentech, Inc.

Completed

A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration

Macular Degeneration

United States, Australia, Czech Republic, France, Germany, Hungary
Genentech, Inc.

Completed

A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Genentech, Inc.

Completed

A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR) (HARBOR)

Age-related Macular Degeneration

United States
Allergan

Terminated

Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Maculopathy | Subfoveal Choroidal Neovascularization

United States
The New York Eye & Ear Infirmary
Genentech, Inc.

Unknown

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy (FVF4193s)

Age Related Macular Degeneration

United States
NeoVista

Unknown

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy (MERITAGE)

Age Related Macular Degeneration

United Kingdom, Israel, United States
Novartis

Terminated

Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

Macular Degeneration | Choroidal Neovascularization

United Kingdom, Spain, Netherlands, Hungary, Italy, Denmark, Belgium, Austria, France, Germany, Poland, Switzerland
Novartis

Completed

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

Macular Degeneration | Choroidal Neovascularization

United States, Canada
Novartis

Completed

Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) (EXCITE)

Age Related Macular Degeneration

Switzerland
Novartis

Completed

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Japan
Novartis

Completed

SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Age Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Asociación para Evitar la Ceguera en México
Centro Medico Issemym

Unknown

Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

Subfoveal Choroidal Neovascularization

Mexico
University Hospital, Basel, Switzerland

Completed

Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV

Age-Related Macular Degeneration | Choroidal Neovascularization

Switzerland
Novartis

Completed

Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Age-Related Macular Degeneration (ARMD)

Switzerland
Incepta Pharmaceuticals Ltd
Institute for Developing Science and Health Initiatives, Bangladesh

Recruiting

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Macular Degeneration | Retinal Degeneration | Diabetic Retinopathy | Diabetic Macular Edema | Macular Edema | Retinal Disease

Bangladesh
Nantes University Hospital
Rennes University Hospital

Not yet recruiting

Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (FAR-WEST)

AMD

France
Dongyang People's Hospital

Recruiting

Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab (JQMMT+RA)

Macular Cystoid Edema

China
Sohag University

Recruiting

Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents

Diabetic Macular Edema

Egypt
Outlook Therapeutics, Inc.

Recruiting

A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

Age-Related Macular Degeneration | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration

United States
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (POYANG)

Choroidal Neovascularization Secondary to Pathologic Myopia

Korea, Republic of, China, Australia, Singapore, Poland, France, Germany, Italy, Taiwan, Hong Kong
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
Ain Shams University

Recruiting

Comparative Study Between IVI of Ranibizumab With and Without Prior ACP in Patients With DME Using OCT-A

Diabetic Macular Edema

Egypt
The University of Texas Medical Branch, Galveston

Recruiting

Intravitreal Injection Site and Perceived Pain

Pain

United States
Novartis Pharmaceuticals

Recruiting

A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

Retinopathy of Prematurity

China
Hoffmann-La Roche

Recruiting

A Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration

Neovascular Age Related Macular Degeneration | nAMD

China
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Branch Retinal Vein Occlusion

China
Sinocelltech Ltd.

Recruiting

This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD

Wet Age-related Macular Degeneration

China
Hoffmann-La Roche

Recruiting

A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Germany, Croatia, Japan, United Kingdom, Spain, United States, Italy, Switzerland, Canada, France, Australia, Singapore, Israel, Puerto Rico, United Arab Emirates, Bulgaria, Chile, Czechia
TOT Biopharm Co., Ltd.
Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.

Recruiting

TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration

China
AbbVie

Recruiting

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

CNV | AMD | nAMD | Wet Age-related Macular Degeneration | wAMD | WetAMD

United States, Puerto Rico, Canada
Ruijin Hospital

Recruiting

Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Diabetic Retinopathy | Cataract Diabetic | Mild Non-proliferative Diabetic Retinopathy

China
Maastricht University Medical Center
Zuyderland Medical Centre

Recruiting

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

Candidiasis, Vulvovaginal | Recurrent Candidiasis of Vagina

Netherlands
Novartis Pharmaceuticals

Recruiting

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Retinopathy of Prematurity

Korea, Republic of
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Wet Age-related Macular Degeneration

China
Qena Faculty of medicine, South Valley University

Recruiting

Ranibizumab Versus Aflibercept for CRVO in Young Patients.

Non-Ischemic Central Retinal Vein Occlusion With Macular Edema

Egypt
Tianjin Medical University Eye Hospital
Hebei Provincial Eye Hospital; Cangzhou Eye Hospital

Recruiting

A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy

Diabetic Retinopathy | Pars Plana Vitrectomy | Ranibizumab | Postoperative Recurrent Vitreous Hemorrhage

China
Wenbin Wei

Recruiting

Anti-VEGF in Real-world

Diabetic Macular Edema | Retinal Vein Occlusion | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic Retinopathy | Choroidal Neovascular Membrane | Neovascular Age-related Macular Edema

China

3

Subscribe